23 results
424B5
ACIU
AC Immune SA
15 Dec 23
Prospectus supplement for primary offering
5:27pm
of directors elects an audit and finance committee from among its members, as a foreign private issuer, the independence of the members of such committee … of Nasdaq Listing Rule 5605(d), which sets forth certain requirements as to the responsibilities, composition and independence of compensation committees
6-K
EX-99.1
ACIU
AC Immune SA
24 May 23
Invitation to the Annual General Meeting 2023 To the Shareholders of AC Immune SA
4:07pm
has been the external auditor of the Company since 2018. They have reconfirmed to the Board that they have the independence required to perform
6-K
EX-99.4
ACIU
AC Immune SA
22 Mar 22
AC Immune Reports Full Year 2021 Financial Results and Provides Corporate Update
7:03am
that a majority of our Board of Directors consists of independent directors. Taking into account all applicable committee independence standards, Douglas Williams … our Board of Directors deemed relevant in determining the director’s independence, including the number of ordinary shares beneficially owned
6-K
EX-99.3
ACIU
AC Immune SA
22 Mar 22
AC Immune Reports Full Year 2021 Financial Results and Provides Corporate Update
7:03am
of Directors or its relevant committee with a statement that we have complied with relevant ethical requirements regarding independence … , and communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, actions taken
6-K
EX-99.2
i6e296l9u
22 Mar 22
AC Immune Reports Full Year 2021 Financial Results and Provides Corporate Update
7:03am
6-K
EX-1.1
2hy7g rdcwzav3glp2o4
5 May 21
Current report (foreign)
4:53pm
6-K
EX-99.3
mtmpgms p5xlz324
23 Mar 21
AC Immune Reports Full-Year 2020 Financial Results and Provides 2021 R&D Outlook
9:06am
6-K
EX-99.4
e5w yio8o5tnt
23 Mar 21
AC Immune Reports Full-Year 2020 Financial Results and Provides 2021 R&D Outlook
9:06am
6-K
EX-1.1
616pv5za imh6wv
8 Sep 20
Current report (foreign)
5:17pm
6-K
EX-99.2
xqbq unn1ak
30 Mar 20
AC Immune Reports Full-Year 2019 Financial Results and Provides 2020 R&D Outlook
9:08am
6-K
EX-99.3
1dijnc7t jfv3gdol6
30 Mar 20
AC Immune Reports Full-Year 2019 Financial Results and Provides 2020 R&D Outlook
9:08am
6-K
EX-99.3
op36s23o6r9
21 Mar 19
Current report (foreign)
7:44am
6-K
EX-99.2
2igyg itcx83h1u
21 Mar 19
Current report (foreign)
7:44am
424B5
j98b47f
20 Jul 18
Prospectus supplement for primary offering
6:03am
424B5
vtb 87uekv1
19 Jul 18
Prospectus supplement for primary offering
4:17pm